ADXS Advaxis Inc.

4.80
-0.15  -3%
Previous Close 4.95
Open 4.95
Price To book 2.65
Market Cap 197116008
Shares 41,065,835
Volume 1,984,912
Short Ratio 30.64
Av. Daily Volume 539,548

SEC filingsSee all SEC filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171079283
  2. 8-K - Current report 171079065
  3. 8-K - Current report 17977085
  4. 8-K - Current report 17953716
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17895022

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 2H 2017.
Axalimogene filolisbac
Cervical cancer
Phase 1/2 updated data due 2H 2017.
Axalimogene filolisbac + durvalumab
Recurrent or refractory HPV-associated cervical cancer and head & neck cancer
Completed the first two dose-escalation cohorts and launched the third dose-escalation cohort in April 2016. Part B combination portion of trial commenced October 2016. Enrollment to be completed by end of 2017.
ADXS-PSA and Keytruda
Castrate-resistant prostate cancer
Announced Phase 3 first patient dosed - February 6, 2017.
Axalimogene filolisbac - AIM2CERV Trial
High-risk, locally advanced cervical cancer
Phase 2 top-line data released October 24, 2016. Second stage was not completed due to the clinical hold in 2015.
Axalimogene filolisbac - GOG 0265 study
Cervical cancer
Phase 1b ongoing.
ADXS-HER2
HER2-driven malignancies - cancer
Phase 2 initiated June 2016. Preliminary update due 2H 2017.
Axalimogene filolisbac
Anal cancer (FAWCETT)

Latest News

  1. Two Abstracts Featuring Advaxis’ Lm-based Candidates Selected for Presentation at the 32nd Annual Society for Immunotherapy Cancer (SITC) Meeting
  2. Advaxis to Present at Cantor Fitzgerald Global Healthcare Conference
  3. Corporate News Blog - EMA Grants Positive CHMP Opinion to Tesaro’s Ovarian Cancer Drug
  4. Today's Research Reports on Stocks to Watch: Advaxis and Heat Biologics
  5. Here's Why Advaxis, Inc. Stock Is Getting Pummeled Today
  6. Advaxis reports 3Q loss
  7. Advaxis Reports Business Update and Third Quarter 2017 Results
  8. What Does Advaxis Inc’s (ADXS) Share Price Indicate?
  9. Advaxis to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival
  10. Advaxis Lead Immunotherapy Candidate Continues to Build Recognition Among Industry Leaders
  11. Advaxis CEO Daniel O'Connor resigns
  12. Advaxis Announces Change in Leadership
  13. Advaxis’ Axalimogene Filolisbac Data Selected for Poster Presentation at ESGO 2017
  14. Advaxis Breaks Down From Key Support Levels
  15. Advaxis to Present at 2017 BIO International Convention
  16. ETFs with exposure to Advaxis, Inc. : June 15, 2017
  17. Advaxis to Be Featured on Worldwide Business with kathy ireland®
  18. Advaxis Details Registrational Trials, EU Regulatory and Commercial Plans at Annual Investor & Analyst Day
  19. Advaxis to Webcast Investor & Analyst Day 2017
  20. Update: Webcast of Advaxis Presentation at Jefferies 2017 Global Healthcare Conference Now Available

SEC Filings

  1. 10-Q - Quarterly report [Sections 13 or 15(d)] 171079283
  2. 8-K - Current report 171079065
  3. 8-K - Current report 17977085
  4. 8-K - Current report 17953716
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 17895022
  6. S-8 - Securities to be offered to employees in employee benefit plans 17750838
  7. 8-K - Current report 17750562
  8. EFFECT - Notice of Effectiveness 17702874
  9. CORRESP [Cover] - Correspondence
  10. S-3/A [Amend] - Registration statement under Securities Act of 1933 17698445